New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:24 EDTPETX, ZTSJefferies to hold a conference
Animal Health Day is being held in New York on March 27.
News For ZTS;PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 29, 2015
08:22 EDTPETXAratana probability of success for AT-002 increased to 95% at William Blair
William Blair increased its probability of success for AT-002 in dogs to 95% after Aratana Therapeutics announced results for the drug after the bell on Friday. The firm also noted that the company’s third small molecule candidate, AT-003 to treat post-surgical pain in dogs, is set to report top-line results in the second half of next month. William Blair keeps an Outperform rating on Aratana shares.
07:55 EDTZTSZoetis could make a bid for IDEXX, says Canaccord
Canaccord hosted investor meetings with IDEXX (IDXX) management, who spoke about new product launches and their market share in light of competitive concerns. Management declined to comment on Zoetis' (ZTS) potential interest in scaling up its animal health diagnostics business, said Canaccord, which noted that it thinks Zoetis could make a bid for IDEXX. Canaccord reiterated its Buy rating and $80 price target on IDEXX shares, citing its cash on the balance sheet, low interest rates, recent CEO stock purchases and new product cycles that skew the risk/reward to the upside.
07:16 EDTPETXAratana Therapeutics shares likely to rise, says Piper Jaffray
Subscribe for More Information
05:49 EDTZTSStocks with implied volatility movement; ZTS QIHU
Subscribe for More Information
June 26, 2015
16:52 EDTPETXAratana Therapeutics up 41% after positive pivotal results for AT-002
Subscribe for More Information
16:41 EDTPETXAratana Therapeutics to resume trading at 4:45 pm ET
Subscribe for More Information
16:16 EDTZTSOn The Fly: Top stock stories for Friday
Subscribe for More Information
16:12 EDTPETXAratana Therapeutics announces positive pivotal results for AT-002
Subscribe for More Information
16:06 EDTPETXAratana Therapeutics trading halted, news pending
Subscribe for More Information
10:00 EDTZTSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Underperform from Market Perform at Bernstein... Apogee Enterprises (APOG) downgraded to Market Perform from Outperform at Northland... Atlas Resource Partners (ARP) downgraded to Underperform from Neutral at BofA/Merrill... Bank of the Ozarks (OZRK) downgraded to Hold from Buy at Drexel Hamilton... China Cord Blood (CO) downgraded to Neutral from Buy at Roth Capital... Citizens Financial (CFG) downgraded to Neutral from Buy at Guggenheim... Community Health (CYH) downgraded to Market Perform from Outperform at Raymond James... Eagle Bancorp (EGBN) downgraded to Hold from Buy at Sandler O'Neill... Fifth Street Senior (FSFR) downgraded to Neutral from Buy at UBS... FireEye (FEYE) downgraded to Equal Weight from Overweight at Barclays... Insight Enterprises (NSIT) downgraded to Underperform at Raymond James... Micron (MU) downgraded to Neutral from Buy at Mizuho... SYNNEX (SNX) downgraded to Hold from Buy at Needham... Swatch Group (SWGAY) downgraded to Equal Weight from Overweight at Barclays... Target (TGT) downgraded to Market Perform from Outperform at BMO Capital... Zoetis (ZTS) downgraded to Market Perform from Outperform at BMO Capital.
09:43 EDTZTSZoetis retraces prior day gains
Subscribe for More Information
09:37 EDTZTSValeant unlikely to pursue Zoetis acquisition, CNBC's Faber says
Subscribe for More Information
09:33 EDTZTSValeant made Zoetis approach as courtesy to Ackman, CNBC reports
Subscribe for More Information
09:33 EDTZTSValeant not going to pursue Zoetis acquisition, CNBC's Faber reports
06:06 EDTZTSZoetis downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
06:02 EDTZTSJPMorgan assumes Valeant pays $60/share for Zoetis
JPMorgan analyst Chris Schott believes Zoetis (ZTS) would bring "an attractive, durable, cash-pay business" to Valeant's portfolio should a merger occur. The Wall Street Journal last night reported that Valeant has approached Zoetis regarding a potential takeover. Schott sees the deal being minimally accretive to near-term earnings, and assumes Valeant pays $60 per share for Zoetis, or a 20% premium to Wednesday's closing price. The analyst thinks any offer would include a substantial equity component given Valeant's levered balance sheet following the Salix acquisition. Schott keeps an Overweight rating on Valeant and a Neutral rating on Zoetis.
June 25, 2015
19:04 EDTZTSOn The Fly: After Hours Movers
Subscribe for More Information
16:13 EDTZTSValeant made preliminary takeover approach to Zoetis, WSJ reports
Valeant Pharmaceuticals (VRX) made a preliminary approach regarding a potential deal to buy Zoetis (ZTS), said The Wall Street Journal, citing people familiar with the matter. The report said it was not clear if Zoetis is open to a sale or what was the company’s reaction to the approach. Zoetis share spiked more than 11% into the close following the report and are up another 1% to $55.95 in after hours trading. Reference Link
15:58 EDTZTSZoetis jumps 11%, halted for circuit breaker after report of Valeant approach
Subscribe for More Information
15:57 EDTZTSValeant made preliminary takeover approach to Zoetis, DJ reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use